文献速递膀胱癌与上尿路尿路上皮癌

保留神经与保留前列腺包膜的膀胱切除术的长期功能与肿瘤学结局:单中心经验

Long-term functional and oncological outcomes of nerve-sparing and prostate capsule-sparing cystectomy: a single-centre experience.
PubMed 文献 · BJU Int · 2019-07-12

单中心研究评估保留神经膀胱前列腺切除术(NSCP)与保留前列腺包膜膀胱切除术(PCSC)治疗器官局限性膀胱癌的技术可行性及肿瘤学与功能结局。2001年4月至2012年6月,60例接受PCSC、47例接受NSCP。中位随访分别为73个月和62个月,5年癌症特异性生存率PCSC组90%、NSCP组78%(P=0.055)。术后3个月日间尿控完全恢复PCSC组54例(90%)、NSCP组24例(51%)(P<0.001);无需治疗即可勃起PCSC组32例(53%)、NSCP组4例(9%)(P<0.001)。

要点

  • PCSC组5年癌症特异性生存率90%,NSCP组78%(P=0.055)。
  • 术后30天内Clavien≥III并发症PCSC组13%、NSCP组21%(P=0.2)。
  • 术后3个月日间尿控完全恢复PCSC组90%、NSCP组51%(P<0.001);无需治疗勃起PCSC组53%、NSCP组9%(P<0.001)。

核心结论

  • NSCP与PCSC适用于部分膀胱癌患者,肿瘤学与功能结局良好。
  • 作者认为这些手术方式应提供给积极性高的患者。

研究设计与样本

  • 单中心研究,2001年4月至2012年6月,60例接受PCSC,47例接受NSCP。
  • PCSC纳入标准:患者充分知情同意且积极性高;膀胱颈经尿道切除阴性;前列腺特异性抗原(PSA)正常(研究第一年定义为<4 ng/dL,后降至2.5 ng/dL);经直肠超声正常,可疑结节行活检。
  • 采用Kaplan-Meier法描绘术后生存结局。

主要发现

  • PCSC组与NSCP组中位随访分别为73个月和62个月,5年癌症特异性生存率PCSC组90% vs NSCP组78%(P=0.055)。
  • 术后30天内Clavien≥III并发症PCSC组13% vs NSCP组21%(P=0.2)。
  • 术后3个月日间尿控完全恢复PCSC组54例(90%)vs NSCP组24例(51%)(P<0.001)。
  • 术后3个月无需任何治疗即可勃起PCSC组32例(53%)vs NSCP组4例(9%)(P<0.001)。

关键数值与推荐

  • PCSC纳入标准:患者充分知情同意且积极性高;膀胱颈经尿道切除阴性;PSA正常(研究第一年<4 ng/dL,后降至2.5 ng/dL);经直肠超声正常,可疑结节行活检。

临床怎么用

  • 作者认为NSCP与PCSC适用于部分膀胱癌患者,应提供给积极性高的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the technical feasibility, oncological and functional outcomes of nerve sparing cystoprostatectomy (NSCP) and prostate capsule-sparing cystectomy (PCSC) for the treatment of organ-confined bladder cancer at a single referral centre. PATIENTS AND METHODS: From April 2001 to June 2012, 60 patients underwent PCSC and 47 were treated with NSCP. Inclusion criteria for PCSC were: fully informed consent for the well-motivated patient; negative transurethral resection of the bladder neck; normal prostatic specific antigen (PSA) level (defined as <4 ng/dL during the first year of the study, which was later lowered to 2.5 ng/dL); and normal transrectal ultrasonography, with biopsy for any suspicious nodule. Patients received a complete oncological and functional follow-up. The Kaplan-Meier method was used to depict survival outcomes after surgery. RESULTS: After a median follow-up of 73 and 62 months for PCSC and NSCP, respectively, the 5-year cancer-specific survival was 90% for the PCSC group and 78% for the NSCP group (P = 0.055). Considering complications within 30 days after surgery, 13% and 21% patients had Clavien ≥III complications in the PCSC and NSCP groups, respectively (P = 0.2). For functional outcomes, at 3 months after surgery, 54 (90%) and 24 (51%) patients reported full recovery of daytime urinary continence in the PCSC and NSCP groups, respectively (P < 0.001); and for erectile function recovery, 32 (53%) and four (9%) patients in the PCSC group and in the NSCP group were respectively potent without any treatment (P < 0.001). CONCLUSIONS: NSCP and PCSC are appropriate for a subset of patients with bladder cancer, with excellent oncological and functional results. These surgical procedures should be proposed to well-motivated patients.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Saad M, Moschini M, Stabile A, et al. Long-term functional and oncological outcomes of nerve-sparing and prostate capsule-sparing cystectomy: a single-centre experience. BJU Int. 2019. PMID: 31220396. doi:10.1111/bju.14850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。